Valuation models
price $92.01 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused52.80 – 74.1061.5549% overvaluedDCF · Perpetuity growth · 10y57.07 – 81.5367.0937% overvaluedDCF · EBITDA exit · 5y73.98 – 80.0776.9420% overvaluedDCF · EBITDA exit · 10y75.10 – 87.1080.8114% overvaluedP/E · peers81.69 – 107.8694.773% undervaluedP/E · own history69.11 – 106.3184.739% overvaluedPEG—61.0751% overvaluedEV/EBITDA · peers62.22 – 95.7693.422% undervaluedEV/Revenue · peers91.75 – 156.97103.5111% undervaluedEarnings power value27.02 – 35.8530.67200% overvaluedWall St. consensus target—100.008% belowCost of capital (WACC)—8.64%—
DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
61.55
Edwards Lifesciences closed at $92.01 — overvalued by 49% vs model.
52.80the model's range74.10
DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
30.67 – 103.51
Wall St. target
100.00 8% below
Above model, 1y
27 of 30 days
How it is valued
Valued asMature & Stable
Moderate growth (~10% recent)Moderate margins (18% net margin)Highly cyclical earnings
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.